Posted by Michael Wonder on 21 Dec 2024
Lexicon announces receipt of complete response letter for Zynquista (sotagliflozin)
20 December 2024 - Confirms previously disclosed and anticipated FDA decision.
Lexicon Pharmaceuticals today announced it has received a complete response letter from the US FDA regarding the new drug application for Zynquista (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease.
